Mebeweryna – skuteczny spazmolityk w leczeniu IBS Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lis 30, 2023
Słowa kluczowe:
zespół jelita nadwrażliwego, zaburzenia osi jelito–mózg, spazmolityki, mebeweryna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zespół jelita nadwrażliwego (IBS) jest przewlekłą chorobą zaliczaną do zaburzeń funkcjonowania osi jelito–mózg. Patofizjologia jest wieloczynnikowa i obejmuje m.in. dysfunkcję osi jelito–mózg, zmiany w składzie mikrobioty jelitowej i zaburzenia psychiczne. W leczeniu istotną rolę oprócz postępowania niefarmakologicznego odgrywają leki rozkurczowe. Spazmolityki są środkami o udowodnionym działaniu i bezpieczeństwie w IBS. Mebeweryna to lek o długiej tradycji stosowania, o potwierdzonej skuteczności i dobrej tolerancji. Jest wskazana w każdej postaci IBS, zwłaszcza z dominacją objawów takich jak ból brzucha i wzdęcia.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Witek, P., & Waluga, M. (2023). Mebeweryna – skuteczny spazmolityk w leczeniu IBS . Medycyna Faktów , 16(3(60), 338-343. https://doi.org/10.24292/01.MF.0323.10
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Mo-til. 2017; 23(2): 151-63. http://doi.org/10.5056/jnm16214.
2. Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160(1): 99-114.e3. http://doi.org/10.1053/j.gastro.2020.04.014.
3. Cassar GE, Youssef GJ, Knowles S et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020; 43(3): E102-22. http://doi.org/10.1097/SGA.0000000000000530.
4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9): 1023-34. http://doi.org/10.1111/apt.12938.
5. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016; 1(2): 133-46. http://doi.org/10.1016/S2468-1253(16)30023-1.
6. Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. Gastroenterol Clin North Am. 2021; 50(2): 445-61. http://doi.org/10.1016/j.gtc.2021.02.007.
7. Mari A, Abu Baker F, Mahamid M et al. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020; 9(3): 685. http://doi.org/10.3390/jcm9030685.
8. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19: S0016-5085(16)00223-7. http://doi.org/10.1053/j.gastro.2016.02.032.
9. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-63. http://doi.org/10.1038/nature12820.
10. Shepherd SJ, Parker FC, Muir JG et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008; 6(7): 765-71. http://doi.org/10.1016/j.cgh.2008.02.058.
11. Tana C, Umesaki Y, Imaoka A et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010; 22(5): 512-9, e114-5. http://doi.org/10.1111/j.1365-2982.2009.01427.x.
12. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018; 13(4): 259-88. http://doi.org/10.5114/pg.2018.78343.
13. Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018; 93(12): 1858-72. http://doi.org/10.1016/j.mayocp.2018.04.032.
14. Alammar N, Stein E. Irritable Bowel Syndrome: What Treatments Really Work. Med Clin North Am. 2019; 103(1): 137-52. http://doi.org/10.1016/j.mcna.2018.08.006.
15. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011; 106(5): 915-22. http://doi.org/10.1038/ajg.2010.480.
16. van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr. 2021; 60(6): 3505-22. http://doi.org/10.1007/s00394-020-02473-0. Erratum in: Eur J Nutr. 2021 Jun 28.
17. Skrzydło-Radomańska B, Szczepanek M, Bartnik W. Zespół jelita drażliwego. Online. (access: 18.05.2023).
18. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15(3): 355-61. http://doi.org/10.1046/j.1365-2036.2001.00937.x.
19. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012; 77(2): 82-90. http://doi.org/10.1016/j.rgmx.2012.04.002.
20. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome – A Systematic Review. J Clin Med. 2022; 11(4): 1044. http://doi.org/10.3390/jcm11041044.
21. Annaházi A, Róka R, Rosztóczy A et al. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20(20): 6031-43. http://doi.org/10.3748/wjg.v20.i20.6031.
22. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996; 10(5): 787-93. http://doi.org/10.1046/j.1365-2036.1996.61203000.x.
23. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23(1): 105-13.
24. Lüttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin. 1980; 6: 437-43. http://doi.org/10.1185/03007998009109464.
25.Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53. http://doi.org/10.3748/wjg.v16.i5.547.
26. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000; 95(4): 999-1007. http://doi.org/10.1111/j.1572-0241.2000.01941.x.
27. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93. http://doi.org/10.1007/s40261-014-0233-y.
28. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54(7): 461-4.
29. Winsemius A, Meuwsen IM, Boon C et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002; 56(9): 659-62.
30. Savarino E, Zingone F, Barberio B et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022; 10(6): 556-84. http://doi.org/10.1002/ueg2.12259.
31. Chapman MA, Grahn MF, Boyle MA et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994; 35(1): 73-6. http://doi.org/10.1136/gut.35.1.73.
32. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34. http://doi.org/10.5114/pg.2021.112681.
33. Banasiewicz T, Kaczmarek E, Maik J et al. Wpływ chronionego maślanu sodu na częstość i nasilenie wybranych objawów klinicznych u chorych z zespołem jelita nadwrażliwego. Gastroenterologia Praktyczna. 2012; 1(14): 48-55.
2. Sperber AD, Bangdiwala SI, Drossman DA et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021; 160(1): 99-114.e3. http://doi.org/10.1053/j.gastro.2020.04.014.
3. Cassar GE, Youssef GJ, Knowles S et al. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs. 2020; 43(3): E102-22. http://doi.org/10.1097/SGA.0000000000000530.
4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9): 1023-34. http://doi.org/10.1111/apt.12938.
5. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016; 1(2): 133-46. http://doi.org/10.1016/S2468-1253(16)30023-1.
6. Berumen A, Edwinson AL, Grover M. Post-infection Irritable Bowel Syndrome. Gastroenterol Clin North Am. 2021; 50(2): 445-61. http://doi.org/10.1016/j.gtc.2021.02.007.
7. Mari A, Abu Baker F, Mahamid M et al. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020; 9(3): 685. http://doi.org/10.3390/jcm9030685.
8. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19: S0016-5085(16)00223-7. http://doi.org/10.1053/j.gastro.2016.02.032.
9. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-63. http://doi.org/10.1038/nature12820.
10. Shepherd SJ, Parker FC, Muir JG et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008; 6(7): 765-71. http://doi.org/10.1016/j.cgh.2008.02.058.
11. Tana C, Umesaki Y, Imaoka A et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010; 22(5): 512-9, e114-5. http://doi.org/10.1111/j.1365-2982.2009.01427.x.
12. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018; 13(4): 259-88. http://doi.org/10.5114/pg.2018.78343.
13. Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018; 93(12): 1858-72. http://doi.org/10.1016/j.mayocp.2018.04.032.
14. Alammar N, Stein E. Irritable Bowel Syndrome: What Treatments Really Work. Med Clin North Am. 2019; 103(1): 137-52. http://doi.org/10.1016/j.mcna.2018.08.006.
15. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011; 106(5): 915-22. http://doi.org/10.1038/ajg.2010.480.
16. van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr. 2021; 60(6): 3505-22. http://doi.org/10.1007/s00394-020-02473-0. Erratum in: Eur J Nutr. 2021 Jun 28.
17. Skrzydło-Radomańska B, Szczepanek M, Bartnik W. Zespół jelita drażliwego. Online. (access: 18.05.2023).
18. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15(3): 355-61. http://doi.org/10.1046/j.1365-2036.2001.00937.x.
19. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012; 77(2): 82-90. http://doi.org/10.1016/j.rgmx.2012.04.002.
20. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B et al. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome – A Systematic Review. J Clin Med. 2022; 11(4): 1044. http://doi.org/10.3390/jcm11041044.
21. Annaházi A, Róka R, Rosztóczy A et al. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20(20): 6031-43. http://doi.org/10.3748/wjg.v20.i20.6031.
22. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther. 1996; 10(5): 787-93. http://doi.org/10.1046/j.1365-2036.1996.61203000.x.
23. Rahman MZ, Ahmed DS, Mahmuduzzaman M et al. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Mymensingh Med J. 2014; 23(1): 105-13.
24. Lüttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin. 1980; 6: 437-43. http://doi.org/10.1185/03007998009109464.
25.Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010; 16(5): 547-53. http://doi.org/10.3748/wjg.v16.i5.547.
26. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000; 95(4): 999-1007. http://doi.org/10.1111/j.1572-0241.2000.01941.x.
27. Hou X, Chen S, Zhang Y et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34(11): 783-93. http://doi.org/10.1007/s40261-014-0233-y.
28. Gilbody JS, Fletcher CP, Hughes IW et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract. 2000; 54(7): 461-4.
29. Winsemius A, Meuwsen IM, Boon C et al. A pharmacokinetic comparison of the modified release capsule and a plain tablet formulation of mebeverine. Int J Clin Pract. 2002; 56(9): 659-62.
30. Savarino E, Zingone F, Barberio B et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2022; 10(6): 556-84. http://doi.org/10.1002/ueg2.12259.
31. Chapman MA, Grahn MF, Boyle MA et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994; 35(1): 73-6. http://doi.org/10.1136/gut.35.1.73.
32. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34. http://doi.org/10.5114/pg.2021.112681.
33. Banasiewicz T, Kaczmarek E, Maik J et al. Wpływ chronionego maślanu sodu na częstość i nasilenie wybranych objawów klinicznych u chorych z zespołem jelita nadwrażliwego. Gastroenterologia Praktyczna. 2012; 1(14): 48-55.